How to Get Repatha (Evolocumab) in Washington State

What Repatha Does and Why LDL Control Matters

Evolocumab is a fully human monoclonal antibody that inhibits PCSK9 (proprotein convertase subtilisin/kexin type 9), a protein that degrades LDL receptors on liver cells. Blocking PCSK9 allows more LDL receptors to remain active, pulling LDL cholesterol out of the bloodstream. The result is a dramatic, sustained reduction in circulating LDL.

The FOURIER trial (N=27,564) demonstrated that adding evolocumab 140 mg every 2 weeks to statin therapy reduced LDL-C by a mean of 59% compared with placebo, from a median baseline of 92 mg/dL down to 30 mg/dL at 48 weeks [1]. That same trial showed a 15% relative risk reduction in the composite cardiovascular endpoint of myocardial infarction, stroke, and cardiovascular death (HR 0.85 to 95% CI 0.79 to 0.92, P<0.001) [1]. Beyond statistics, patients with established ASCVD who remain above LDL targets on maximally tolerated statin therapy carry a measurable residual risk that evolocumab directly addresses.

The FDA approved evolocumab in August 2015 under the brand name Repatha for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and established cardiovascular disease requiring additional LDL lowering [2]. The ACC/AHA cholesterol guideline recommends PCSK9 inhibitors for very-high-risk ASCVD patients whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe therapy [3].

A 2019 analysis published in the Journal of the American College of Cardiology examined cost-effectiveness thresholds and confirmed that patients with baseline LDL above 100 mg/dL on maximum statin derive the greatest absolute cardiovascular benefit from PCSK9 inhibition [4]. Washington prescribers and payers use this kind of evidence when evaluating PA requests.

Who Qualifies for Repatha in Washington

Washington payers, including Medicaid and most commercial plans, align their coverage criteria closely with the ACC/AHA guidelines and FDA labeling. Qualifying conditions fall into two broad categories.

Familial hypercholesterolemia. HeFH affects roughly 1 in 250 people; HoFH affects approximately 1 in 300,000 [5]. Diagnosis is established using the Dutch Lipid Clinic Network criteria or genetic testing confirming a pathogenic LDLR, APOB, or PCSK9 variant. Most WA payers require documented LDL-C at or above 100 mg/dL (HeFH) despite maximally tolerated statin, or any LDL-C in HoFH.

Established ASCVD. This includes prior MI, ischemic stroke, symptomatic peripheral artery disease, or documented coronary artery disease. Payers typically require LDL-C at or above 70 mg/dL despite high-intensity statin therapy (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) for at least 90 days, sometimes with ezetimibe added as well [3].

Statin intolerance. Patients who cannot tolerate any statin due to confirmed myopathy or persistent CK elevation above 10 times the upper limit of normal may qualify without the statin-trial requirement, provided the intolerance is documented in the medical record with specific symptom dates, CK values, and the names of statins attempted [6].

Washington Apple Health (Medicaid) follows the Preferred Drug List managed by the Washington State Pharmacy and Therapeutics Committee. As of 2024, evolocumab is covered under Medicaid with prior authorization when the patient has HeFH or established ASCVD, has tried and failed or is intolerant to at least one high-intensity statin, and the prescribing provider submits supporting labs and diagnosis documentation [7].

Labs and Documentation Required Before Prescribing

Getting Repatha approved in Washington requires assembling a specific clinical file before or at the time of the PA submission.

Fasting lipid panel. A fasting lipid panel drawn within the past 90 days is standard. The result must show LDL-C at or above the payer's threshold despite documented statin use. Some payers accept a non-fasting panel if LDL is calculated directly rather than estimated via Friedewald equation [8].

Statin trial records. The medical record should include the statin name, dose, duration (minimum 90 days for most payers), and any dose adjustments. If the patient is statin-intolerant, documented trial of at least two different statins at the lowest available dose is typically required, along with symptom notes and CK lab values [6].

Diagnosis documentation. HeFH requires either a clinical score (Dutch Lipid Clinic Network score of 6 or above) or a positive genetic test result. ASCVD requires supporting records such as a catheterization report, imaging, or prior hospital discharge summary confirming the qualifying event [3].

Ezetimibe trial. Most Washington commercial payers require a concurrent or prior 90-day trial of ezetimibe 10 mg before approving evolocumab for ASCVD. The ACC/AHA guideline supports this stepwise approach [3]. Exceptions exist for patients with confirmed HoFH, where ezetimibe has limited efficacy.

Prescriber attestation. The prescribing clinician signs a form confirming that the patient's LDL remains uncontrolled despite optimized therapy. Some payers add a cardiovascular risk stratification requirement using the ACC/AHA Pooled Cohort Equations [9].

How to Get a Repatha Prescription in Washington: Step by Step

Washington residents have two practical routes: an in-person visit with a cardiologist, lipidologist, or primary care provider, or a telehealth consultation.

Step 1: Choose Your Prescriber Type

Washington state law permits MD, DO, NP (nurse practitioner), and PA (physician assistant) licensees to prescribe Schedule and non-schedule medications within their scope of practice, including evolocumab [10]. NPs in Washington practice under full practice authority, meaning they do not need physician supervision to prescribe. PAs require a practice agreement, but prescribing PCSK9 inhibitors is well within standard PA scope for cardiology and primary care settings.

Telehealth prescribing of evolocumab is permitted in Washington. The state enacted permanent telehealth parity legislation (SB 5385, 2021) requiring commercial insurers to cover telehealth visits at parity with in-person visits [10]. A telehealth provider licensed in Washington can evaluate your lipid history, order labs, and submit a PA on your behalf without you ever entering a clinic.

Step 2: Gather Your Records

Before your first appointment, collect your most recent lipid panel, any prior statin prescription records, current medication list, and any cardiac event documentation. Sending these ahead of the visit shortens the consultation and allows the prescriber to begin the PA process immediately. Missing documentation is the single most common reason PA approvals are delayed in Washington.

Step 3: The Prescriber Submits Prior Authorization

Once the prescriber confirms you meet clinical criteria, the PA request goes to your insurer. Washington law requires commercial insurers to respond to non-urgent PA requests within 3 business days [11]. Medicaid PA decisions under Washington Apple Health typically take 5 to 10 business days. A PA approval is usually valid for 12 months before renewal is required.

If the initial PA is denied, Washington's Insurance Commissioner rules require the insurer to provide a written explanation, and you have the right to a free external review [11]. A clinical appeal with a cardiologist letter resolves the majority of initial denials.

Step 4: Pharmacy Dispensing

Repatha is a specialty biologic dispensed through specialty pharmacies, not standard retail chains. Amgen's own specialty pharmacy network (AmgenAssist) and major specialty distributors such as CVS Specialty, Accredo (Evernorth), and Walgreens Specialty all serve Washington residents. The medication ships refrigerated via overnight carrier directly to your home or a clinical address.

Standard retail pharmacies in Washington do not routinely stock evolocumab, but they can order it with 24 to 72 hours' lead time if you prefer in-person pickup. The device arrives as a single-use SureClick autoinjector (140 mg/mL) or a Pushtronex on-body infusor (420 mg/3.5 mL) for the monthly dose [2].

Step 5: Cost Assistance

Amgen's list price for Repatha is approximately $700 per month. For commercially insured patients, Amgen's copay card (AmgenAssist) can reduce out-of-pocket costs to as low as $0 per month for eligible patients [2]. Washington Medicaid beneficiaries with an approved PA pay standard Medicaid cost-sharing, which is minimal. Uninsured patients may qualify for the Amgen Safety Net Foundation program, which provides free Repatha to patients below 500% of the federal poverty level.

Telehealth Options for Repatha in Washington

Washington's telehealth infrastructure is among the most developed in the western United States. The 2021 parity law and Washington's full practice authority for NPs together make telehealth a genuinely convenient path to a Repatha prescription.

A typical telehealth pathway looks like this: you complete an intake form listing your cardiovascular history, current medications, and prior lipid labs. A licensed Washington prescriber reviews your records synchronously (video) or, for established patients, asynchronously. If labs are current and clinical criteria are met, the prescriber places the PA request within the same encounter. If labs are outdated, the prescriber orders them through a patient service center or orders you to a LabCorp or Quest draw site near your Washington address.

Patients using telehealth for Repatha initiation in Washington should confirm that the platform's prescribers hold an active Washington Medical Commission or Nursing Commission license. Out-of-state telehealth providers are not automatically licensed in Washington and cannot prescribe for WA residents unless they hold a WA license or a WA telemedicine license specifically [10].

Transferring a Repatha Prescription to Washington

If you recently moved to Washington and have an existing Repatha prescription from another state, the transfer process depends on your insurance status.

Commercial insurance transfers require a new PA submission to your Washington-based plan. Even if you carried the same insurer across state lines, Washington coverage criteria may differ from your prior state's formulary rules. Your new Washington prescriber will need to submit a fresh PA using your Washington plan's forms.

Medicaid transfers work differently. Washington Apple Health does not honor out-of-state Medicaid PAs. You must re-enroll in Washington Medicaid, establish care with a WA-licensed prescriber, and submit a new PA. Under the Affordable Care Act, Washington Medicaid enrollment for qualifying individuals can be completed online through Washington Healthplanfinder, and coverage is typically effective the first of the following month.

Specialty pharmacy transfers are straightforward. Contact your current specialty pharmacy and request a transfer to a Washington-licensed specialty pharmacy, or keep the same national specialty pharmacy if it serves WA. Most national specialty pharmacies (CVS Specialty, Accredo, Walgreens Specialty) are licensed to ship to Washington addresses. The physical prescription transfers electronically between pharmacy systems.

503A Compounding Pharmacies and Evolocumab in Washington

503A pharmacies are state-licensed compounding pharmacies operating under individual prescription requirements set by the FDA and state boards of pharmacy. Washington's Pharmacy Quality Assurance Commission licenses 503A pharmacies within the state [12].

Evolocumab is a recombinant human monoclonal antibody produced through mammalian cell culture. Compounding a biologic of this complexity is not feasible in a standard 503A pharmacy. The FDA has not identified evolocumab as a drug suitable for pharmacy compounding, and no 503A pharmacy in Washington ships a compounded version of evolocumab. If you encounter a pharmacy claiming to sell compounded evolocumab, that product is not FDA-approved and carries unknown safety and efficacy risks.

The 503A pathway does apply to related lipid medications. Some Washington 503A pharmacies compound extended-release niacin, certain fibrates, or bile acid sequestrant formulations as adjunct therapy. For evolocumab specifically, the branded Amgen product dispensed through a licensed specialty pharmacy is the only valid option in Washington.

What to Expect After Starting Repatha

LDL-C reductions become measurable at 4 weeks. The FOURIER trial documented a 59% mean reduction in LDL-C at 48 weeks [1]. Most patients see their LDL nadir within 4 to 8 weeks of the first injection. The drug is administered subcutaneously in the abdomen, upper arm, or thigh. Injection site reactions occur in approximately 3.2% of patients vs. 3.0% placebo in FOURIER, making them clinically marginal [1].

Your prescriber should recheck a fasting lipid panel 4 to 12 weeks after the first dose to confirm response and satisfy payer requirements for continuation authorization [3]. Washington payers typically require a follow-up lipid result showing LDL below the threshold (usually 70 mg/dL for ASCVD or below 100 mg/dL for HeFH) as a condition of annual PA renewal.

Nasopharyngitis (10.5% vs. 9.7% placebo) and upper respiratory infection (9.3% vs. 8.7% placebo) were the most common adverse events in FOURIER, both occurring at rates only marginally above placebo [1]. No significant neurocognitive signal emerged in the FOURIER dataset; a dedicated EBBINGHAUS sub-study (N=1,974) found no statistically significant difference in cognitive composite scores between evolocumab and placebo groups over a median 19 months [13].

Long-term cardiovascular data from FOURIER's open-label extension showed that patients who received evolocumab for a median of 5 years had a 23% lower rate of the primary composite endpoint compared with those who switched from placebo to evolocumab later, suggesting early and sustained LDL lowering produces compounding benefit over time [14].

Monitoring and Follow-Up for Washington Patients

After the 4 to 12 week lipid recheck, Washington prescribers typically schedule follow-up every 6 to 12 months. At each visit the clinician should review LDL-C, confirm injection adherence, assess for injection-site reactions, and reassess cardiovascular risk. No routine hepatic or renal monitoring is required based on the FDA label, as evolocumab is not metabolized by the liver through CYP450 enzymes [2].

Patients on Repatha who also take statins should continue statin therapy unless intolerance is documented. The FOURIER population was entirely on background statin therapy, meaning the trial's cardiovascular benefit data apply specifically to combination use [1]. Stopping the statin and relying on evolocumab alone is not supported by current guideline recommendations [3].

For WA Medicaid patients, the PA renewal process begins 60 to 90 days before the authorization expires. Your specialty pharmacy or clinical team should initiate this automatically, but confirming the timeline with your prescriber avoids gaps in supply.